Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations;Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2012

Anales de Pediatria

Volumn 76, Issue 1, 2012, Pages

  Moreno Perez D ^a   Alvarez Garcia F J ^a   Aristegui Fernandez J ^a   Barrio Corrales, F ^a   Cilleruelo Ortega, M J ^a   Corretger Rauet, J M ^a   Gonzalez Hachero J ^a   Hernandez Sampelayo Matos T ^a   Merino Moina M ^a   Ortigosa Del Castillo, L ^a   Ruiz Contreras, J ^a  

^a Hospital Clínico   (Spain)

Author keywords

Catch up immunization schedules; Vaccine preventable diseases; Vaccines, Immunization schedule

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; WART VIRUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ARTICLE; CHILD; CLINICAL PROTOCOL; DRUG EFFICACY; FUNDING; HEALTH CARE ORGANIZATION; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; PRACTICE GUIDELINE; RISK ASSESSMENT; SPAIN; DRUG DOSE REGIMEN;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; SPAIN; VACCINES;

EID: 84856022584     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2011.10.007     Document Type: Article

References (139)

1. J. Mars Bermúdez, D. van Esso Arbolave, D. Moreno-Pérez, M. Merino Moína, F. Álvarez García, and M.J. Cilleruelo Ortega Calendario de vacunaciones de la AEP: Recomendaciones An Pediatr (Barc) 74 2011 132.e1 132.e19
2. Calendarios de vacunación de las ciudades y comunidades autónomas [último acceso 12 Oct 2011)]. Disponible en: http://www.aepap.org/vacunas/calvaces.htm
3. Centers for Disease Control and Prevention (CDC) Recommended immunization schedules for persons aged 0-18 years-United States, 2011 MMWR 60 2011 1 4
4. Centers for Disease Control and Prevention (CDC) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: Immunization of infants, children, and adolescents MMWR 54 No.RR-16 2005 1 33
5. J.C. Tejedor, M. Moro, J. Ruiz Contreras, J. Castro, J.A. Gómez-Campderá, and M.L. Navarro Immunogenicity and reactogenicity of primary immunization with hexavalent diphteria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of meningococcal C-tetanus toxoid conjugate vaccine Pediatr Infect Dis J 25 2006 713 720 (Pubitemid 44162129)
6. Centers for Disease Control and Prevention (CDC) Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMRW Recomm Rep 60 RR-2 2011 1 60
7. ®) as a single-booster immunization for the prevention of tetanus, diphteria, and pertusis in children (aged = o > 4 years), adolescents, and adults Pediatr Drugs 13 2011 133 135
8. Centers for Disease Control and Prevention (CDC) Updated recommendations for use of tetanus toxoid, reduced diphteria toxoid and acellular pertusis (Tdap) vaccine from the Advisory Committee on the Immunization Practices (ACIP), 2010 MMRW Morb Mortal Wkly Rep 60 2011 13 15
9. F. Zepp, U. Heininger, J. Mertsola, E. Bernatowska, N. Guiso, and J. Roord Rationale for pertussis booster vaccination throughout life in Europe Lancet Infect Dis 11 2011 557 570
10. Ponencia de Programa y Registro de Vacunaciones de 4 de Febrero del 2010. Propuesta de recomendación para la sustitución de la vacuna DTPa, como quinta dosis por una vacuna dTpa, en el Calendario de vacunación infantil recomendado por el Consejo Interterritorial del Sistema Nacional de Salud (CISNS). Documento Interno [último acceso 12 Oct 2011]. Madrid, 16 de Febrero de 2010. Disponible en: http://www.aragon.es/estaticos/ GobiernoAragon/Departamentos/SaludConsumo/Profesionales/13-SaludPublica/ 20-Programas-Salud/Propuesta-recomendacion-sustitucion-vacuna-DTPa.pdf
11. K.R. Broder, M.M. Cortese, J.K. Iskander, K. Kretsinger, B.L. Slade, and K.H. Brown Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP) MMRW Recomm Rep 55 RR-03 2006 1 34
12. J.G. Liese, N. Rieber, T. Malzer, M. Ocak, D.R. Johnson, and M. Decker Reactogenicity of tetanus, diphteria, 5 component acellular pertusis vaccine administered as sixth consecutive acellular pertusis vaccine dose to adolescents Pediatr Infect Dis J 29 2010 1067 1071
13. C.U. Meyer, P. Habermehl, M. Knuf, B. Hoet, J. Wolter, and F. Zepp Immunogenicity and reactogenicity of acellular pertusis booster vaccines in children Hum Vaccin 4 2008 203 209
14. J. Mertsola, O. Van Der Meeren, Q. He, A. Linko-Parvinen, G. Ramakrishnam, and L. Mannermaa Decennial administration of a reduced antigen content diphteria and tetanus toxoids and acellular pertusis vaccine in young adults Clin Infect Dis 51 2010 656 662
15. Wolters Kluwer-Pharma Solutions. Drugs perspectives in vaccinology. Bortedella pertussis: Is there a need for expanded immunisation programme? Science Communications, Rueil-Malmaison Cedex-France;2011:1-18.
16. Vacunación en adultos. Recomendaciones vacunas difteria y tétanos. Actualización 2009 [último acceso 12 Oct 2011]. Disponible en: http://www.msps.es/ciudadanos/proteccionSalud/vacunaciones/docs/ TetanosDifteria-2009.pdf
17. K.D. Forsyth, M. Campins-Martí, J. Caro, J.D. Cherry, D. Greenberg, and N. Guiso New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative Clin Infect Dis 39 2004 1802 1809 (Pubitemid 39657260)
18. C.M. Healy, M.A. Rench, and C.J. Baker Implementation of cocooning against pertussis in a high-risk population Clin Infect Dis 52 2011 157 162
19. Conseil Supérieur de la Santé. Vaccination anticoquelucheuse (fichier 8547). Vaccination de ladulte (2009) [último acceso 12 Oct 2011]. Disponible en: http://www.belgium.be/en/health/
20. A. Larrauri, R. Cano, M. García, and S. De Mateo Impact and effectiveness of meningococcal conjugate vaccine following its introduction in Spain Vaccine 23 2005 4097 4100 (Pubitemid 40814584)
21. Red Nacional de Vigilancia Epidemiológica de España Enfermedad meningocócica en España. Análisis de la temporada 2003-2004. Madrid Mayo de 2005 [último acceso 12 Oct 2011]. Disponible en: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/ fd-vigilancias-alertas/boletines.shtml
22. Dirección General de Salud Pública y Alimentación Consejería de Sanidad y Consumo de la Comunidad de Madrid. Infecciones que causan meningitis. 2005 [último acceso 12 Oct 2011]. Disponible en: http://www.madrid.org/cs/Satellite?pagename=PortalSalud/Page/PTSA-home
23. Grupo de Trabajo de Enfermedad Meningocócica de la Ponencia de Programa y Registro de Vacunación: Situación actual de la enfermedad meningocócica en España. Modificación de la pauta de vacunación frente a meningococo C [último acceso 12 Oct 2011]. Disponible en: http://www.msc.es/ciudadanos/proteccionSalud/infancia/docs/MenC- MARZO-2006.pdf
24. H. Campbell, R. Borrow, D. Salisbury, and E. Miller Meningococcal C conjugate vaccine: the experience in England and Wales Vaccine 27 Suppl 2 2009 B20 B29
25. H. Campbell, N. Andrews, R. Borrow, C. Trotter, and E. Miller Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity Clin Vaccine Immunol 17 2010 840 847
26. Instituto de Salud Carlos III, Red Nacional de Vigilancia Epidemiológica. Boletín Epidemiológico Semanal en RED. Información de la enfermedad meningocócica 37/2011 [último acceso 12 Oct 2011]. Disponible en: http://www.isciii.es/ISCIII/es/contenidos/ fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/boletines.html
27. Menveo® (Novartis). Ficha técnica [último acceso 12 Oct 2011]. Disponible en: www.ema.europa.eu/docs/es-ES/document-library/EPAR- Product-Information/human/001095/WC500090147.pdf
28. European Centre for Disease Control and Prevention (ECDC). Measles [último acceso 12 Oct 2011]. Disponible en: http://www.ecdc.europa.eu/en/ healthtopics/measles/Pages/index.aspx
29. a Edición. Publicación científica y técnica, n. 605. OMS. Washington, 2007.
30. a edición. Royal College of Paediatrics and child health 2011. Oxford Universty Press Inc., New York, 2011;624-7.
31. Consejería de Salud de la Junta de Andalucía. Secretaría General de Salud Pública y Participación: Servicio de Vigilancia Epidemiológica de Andalucía. Protocolo de Alerta Epidemiológica por Sarampión-adaptado. Última modificación de 24 de Abr del 2008. Sevilla, 2011
32. Calendario de vacunaciones del Consejo Interterritorial del Sistema Nacional de Salud 2007 [último acceso 12 Oct 2011]. Disponible en: http://www.msps.es/ciudadanos/proteccionSalud/infancia/docs/c2007.pdf
33. ® (EPAR, última actualización: 14 de septiembre de 2011) [último acceso 12 Oct 2011]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000703/human-med-000805.jsp&mid=WC0b01ac058001d124
34. Ficha técnica de Cervarix® (EPAR, última actualización: Oct de 2010) [último acceso 12 Oct 2011]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000721/human-med-000694.jsp&mid=WC0b01ac058001d124
35. Ficha técnica Gardasil® (FDA, última actualización: 22 de diciembre de 2010) [último acceso 12 Oct 2011]. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm237941.htm
36. Centers for Diseases Control and Prevention FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 59 2010 630 632
37. B. Romanowski Patricia Study Group Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types: end of- study results 26th International Papillomavirus Conference Montreal, Canadá. 3-8 Julio 2011
38. T. Vesikari, P. Van Damme, N. Lindblad, U. Pfletschinger, D. Radley, and D. Ryan An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age Pediatr Infect Dis J 29 2010 314 318
39. C.M. Wheeler, B.M. Harvey, M.E. Pichichero, M.W. Simon, S.P. Combs, and M.M. Blatter Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial Pediatr Infect Dis J 30 2011 e225 e234
40. B. Lu, A. Kumar, X. Castellsagué, and A.R. Giuliano Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis BMC Infect Dis 11 2011 13
41. L.E. Markowitz, S. Hariri, E.R. Unger, M. Saraiya, S.D. Datta, and E.F. Dunne Post-licensure monitoring of HPV vaccine in the United States Vaccine 28 2010 4731 4737
42. World Health Organization Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009 Wkly Epidemiol Rec 84 2009 325 332
43. J.M. Palefsky Human papillomavirus-related disease in men: not just a women's issue J Adolesc Health 46 Suppl. 4 2010 S12 S19
44. H.W. Chesson, D.U. Ekwueme, M. Saraiya, E.F. Dunne, and L.E. Markowitz The cost-effectiveness of male HPV vaccination in the United States Vaccine 2011 [Epub ahead of print]
45. Web de la Agencia Europea de Medicamentos. Ficha técnica de Synflorix (última actualización: 16 de agosto de 2011) [último acceso 12 Oct 2011]. Disponible en: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/000973/human-med-001071. jsp&mid=WC0b01ac058001d124
46. Web de la Agencia Europea de Medicamentos Ficha técnica de Prevenar13 (última actualización: 09 de diciembre de 2009) [último acceso 12 Oct 2011]. Disponible en: http://www.ema.europa.eu/ docs/es-ES/document-library/EPAR-Product-Information/human/001104/WC500057247. pdf
47. J. Picazo, J. Ruiz-Contreras, J. Casado-Flores, E. Giangaspro, F. del Castillo, and T. Hernández-Sampelayo Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar Clin Vaccine Immunol 18 2011 89 94
48. C. Muñoz-Almagro, P. Ciruela, C. Esteva, F. Marco, M. Navarro, and R. Bartolomé Serotypes and clones causing invasive pneumococccal disease before the use of new conjugate vaccines in Catalonia, Spain J Infect 63 2011 151 162
49. J. Picazo, J. Ruiz-Contreras, J. Casado-Flores, S. Negreira, M.J. García de Miguel, T. Hernández-Sampelayo HERACLES Study Group Distribution by clinical presentation of serotypes isolated from pediatric invasive pneumococcal diseases in 2009-2010, Madrid, Spain 29th Annual Meeting of European Society for Padediatric Infectious Diseases (ESPID) La Haya, Holanda. 7-11 Junio 2011
50. Conselleria de Sanitat de la Generalitat Valenciana. Direcció General de Salut Pública. Informe de Enfermedad neumocócica invasora 2008 [último acceso 12 Oct 2011]. Disponible en: http://www.san.gva.es/cas/prof/homeprof.html
51. J. Picazo, J. Ruiz-Contreras, J. Casado-Flores, S. Negreira, M.J. García de Miguel, T. Hernández-Sampelayo HERACLES Study Group The Heracles study (2007-2010): a prospective hospital-based surveillance of serotypes causing pediatric invasive pneumococcal disease in Madrid, Spain 29th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID) La Haya, Holanda. 7-11 Junio 2011
52. J. Picazo, J. Ruiz-Contreras, J. Casado-Flores, S. Negreira, M.J. Garcia-de-Miguel, T. Hernández-Sampelayo HERACLES Study Group Distribution by age of serotypes isolated from pediatric invasive pneumococcal diseases in 2009-2010 in Madrid, Spain 29th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID) La Haya, Holanda. 7-11 Junio 2011
53. C. Esteva, L. Selva, M.F. de Sevilla, J.J. García-García, R. Pallarés, and C. Muñoz-Almagro Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989-2008) Clin Microbiol Infect 17 2011 1441 1444
54. J. Picazo, J. Ruiz-Contreras, J. Casado Flores, S. Negreira, F. del Castillo, and T. Hernández-Sampelayo Laboratory-based, 2-year surveillance of pediatric parapneumonic empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in Madrid Pediatr Infect Dis J 30 2011 471 474
55. G. Hanquet, E. Kissling, A. Fenoll, R. George, A. Lepoutre, and T. Lernout Pneumococcal serotypes in children in 4 European countries Emerg Infect Dis 16 2010 1428 1439
56. A. Fenoll, L. Aguilar, M.D. Vicioso, M.J. Jiménez, O. Robledo, and J.J. Granizo Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008 Antimicrob Agents Chemother 54 2010 5387 5390
57. C. Muñoz-Almagro, C. Esteva, M. Fernández de Sevilla, L. Selva, A. Gene, and R. Pallarés Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona J Infect 59 2009 75 82
58. J. Picazo, J. Ruiz-Contreras, B. Hernández, F. Sanz, A. Gutiérrez, and E. Cercenado Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007-2009) laboratory-based surveillance in Madrid Vaccine 29 2011 1770 1776
59. D. Tarragó, L. Aguilar, R. García, M.J. Giménez, J.J. Granizo, and A. Fenoll Evolution of clonal and susceptibility profiles of serotype 19A Streptococcus pneumoniae among invasive isolates from children in Spain, 1990 to 2008 Antimicrob Agents Chemother 55 2011 2297 2302
60. R. Singleton, J. Wenger, J.A. Klejka, L.R. Bulkow, A. Thompson, and D. Sarkozys Impact of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Alaska native children: results of a clinical trial 29th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID) La Haya, Holanda. 7-11 Junio 2011
61. Health Protection Agency (HPA). Current epidemiology of Invasive Pneumococcal Disease [último acceso 12 Oct 2011]. Disponible en: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/ EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/
62. st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, EE. UU. 17-20 septiembre 2011 Abstract G1-538
63. Jacobs MR, Bajaksouzian S, Good CE, Windau AR, González B. Evolution of Streptococcus pneumoniae serotypes following introduction of the 13-valent conjugate pneumococcal vaccine. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, EE. UU. 17-20 septiembre 2011. Abstract G3-773.
64. st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, EE. UU. 17-20 septiembre 2011 Abstract G3-1709
65. S. Esposito, S. Tansey, A. Thompson, A. Razmpour, J. Liang, and T.R. Jones Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers Clin Vaccine Immunol 17 2010 1017 1026
66. J.Y. Hughes, M.D. Snape, C.L. Klinger, E. Daniels, H. Layton, and T.M. John Immunogenicity of booster doses of 13-valent pneumococcal conjugate and Hib/MenC vaccines given at 12 months of age in the UK 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID) Bruselas, Bélgica. 9-13 Junio 2009
67. Actualización en vacunación antineumocócica. Recomendaciones del Comité Asesor de Vacunas de la Asociación Española de Pediatría [último acceso 12 Oct 2011]. Disponible en: http://vacunasaep.org/documentos/actualizacion-en-vacunacion- antineumococica-2010-recomendaciones-del-comite-asesor-de-vac
68. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Prevention of pneumococcal disease among infants and children - Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine MMWR 59 RR11 2010 1 18
69. S.S. Shah, S.M. Wood, X. Luan, and A.J. Ratner Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella Pediatr Infect Dis J 29 2010 199 204
70. M.A. Reynolds, B.M. Watson, K.K. Plott-Adams, A.O. Jumaan, K. Galil, and T.J. Maupin Epidemiology of varicella hospitalizations in the United States, 1995-2005 J Infect Dis 197 2008 S120 S126
71. R. Patel, H.J. Binns, and S.T. Shulman Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era J Pediatr 144 2004 68 74 (Pubitemid 38091424)
72. M. Marin, J.X. Zhang, and J.F. Seward Near elimination of varicella deaths in the US after implementation of the vaccination program Pediatrics 128 2011 214 220
73. Comité Asesor de Vacunas de la Comunidad de Madrid Servicio Madrileño de Salud. Informe sobre varicela en la Comunidad de Madrid, 2010 [último acceso 12 Oct 2011]. Disponible en: http://www.madrid.org/cs/ Satellite?language=es&pagename=PortalSalud%2FPage%2FPTSA-home
74. M. García Cenoz, J. Castilla, F. Irisarri, M. Arriazu, and A. Barricarte Impacto de la vacunación universal frente a la varicela en Navarra, 2006-2010 An Sist Sanit Navar 34 2011 193 202
75. B.D. Tugwell, L.E. Lee, H. Gillette, E.M. Lorber, K. Hedberg, and P.R. Cieslak Chickenpox outbreak in highly vaccinated school population Pediatrics 113 2004 455 459 (Pubitemid 38280783)
76. O. Bayer, U. Heininger, C. Heiligenstzer, and R. Von Kries Metaanalysis of vaccine effectiveness in varicella outbreaks Vaccine 25 2007 6655 6660 (Pubitemid 47332733)
77. S.S. Chaves, P. Gargiullo, J.X. Zhang, R. Civen, D. Guris, and L. Mascota Loss of vaccine-induced immunity to varicella vaccine over time N Engl J Med 356 2007 1121 1129 (Pubitemid 46425596)
78. S.S. Chaves, J. Zhang, R. Civen, B.M. Watson, T. Carbajal, and D. Perella Varicella disease among vaccinated persons. Clinical and epidemiological characteristics, 1997-2005 J Infect Dis 197 2008 S127 S131
79. B. Kuter, H. Matthews, H. Shinefield, S. Black, P. Dennehy, and B. Watson Ten year follow-up of healthy children who received one or two injections of varicella vaccine Pediatr Infect Dis J 23 2004 132 137 (Pubitemid 38222785)
80. D.E. Michalik, S.P. Steinberg, P.S. Larussa, K.M. Edwards, P.F. Wright, and A.M. Arvin Primary vaccine failure after 1 dose of varicella vaccine in healthy children J Infect Dis 197 2008 944 949 (Pubitemid 351590021)
81. M. Marin, D. Guris, S.S. Chaves, S. Schmid, and J.F. Seward Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 56 2007 1RR 40RR
82. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: Recommendations for use of varicella vaccines in children, including recommendations for a routine 2-dose varicella immunization schedule Pediatrics 120 2007 221 231
83. B. Watson Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine J Infect Dis 197 2008 143 146
84. M. Brisson, G. Melkonyan, M. Drolet, G. De Serres, R. Thibeault, and P. De Wals Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster Vaccine 28 2010 3385 3397
85. M.S. Patel, A. Gebremariam, and M.M. David Herpes zoster-related hospitalization and expenditures before and after introduction on the varicella vaccine in the United States Infect Control Hosp Epidemiol 29 2008 1157 1163
86. K.S. Carville, M.A. Ridell, and H.A. Kelly A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia Vaccine 28 2010 2532 2538
87. M.A. Reynolds, S.S. Chaves, and R. Harpaz The impact of the varicella vaccination program on herpes zoster epidemiology in the United States a review J Infect Dis 197 Suppl 2 2008 224 227
88. D. Gilden Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia J Intern Med 259 2011 496 506
89. U.D. Parashar, C.J. Gibson, J.S. Bresse, and R.I. Glass Rotavirus and severe childhood diarrhea Emerg Infect Dis 12 2006 304 306
90. D.I. Bernstein Rotavirus overview Pediatr Infect Dis J 28 2009 S50 S53
91. Centers for Disease Control and Prevention (CDC) Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 58 RR-2 2009 1 25
92. Centers for Disease Control and Prevention (CDC) Reduction in rotavirus after vaccine introduction - United States, 2000-2009 MMWR Morb Mortal Wkly Rep 58 2009 1146 1149
93. World Health Organization (WHO) Rotavirus vaccines: an update Wkly Epidemiol Rec 84 2009 533 558
94. S.N. Desai, D.B. Esposito, E.D. Shapiro, P.H. Dennehy, and M. Vázquez Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA Vaccine 28 2010 7501 7506
95. J.E. Tate, J.D. Mutuc, C.A. Panozzo, D.C. Payne, M.M. Cortese, and J.E. Cortes Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006 Pediatr Infect Dis J 30 Suppl. 1 2011 30 34
96. A. Gagneur, E. Nowak, T. Lemaitre, J.F. Segura, N. Delaperrire, and L. Abalea Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhoea: the IVANHOE study Vaccine 29 2011 3753 3759
97. M. Quintanar-Solares, C. Yen, V. Richardson, M. Esparza-Aguilar, U.D. Parashar, and M.M. Patel Impact of rotavirus vaccination on diarrhea-related hospitalizations among children < 5 years of age in Mexico Pediatr Infect Dis J 30 Suppl 1 2011 11 15
98. V. Richardson, J. Hernandez-Pichardo, M. Quintanar-Solares, M. Esparza-Aguilar, B. Johnson, and C.M. Gomez-Altamirano Effect of rotavirus vaccination on death from childhood diarrhea in Mexico N Engl J Med 362 2010 299 305
99. J.P. Buttery, S.B. Lambert, K. Grimwood, M.D. Nissen, E.J. Field, and K.K. McCartney Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule Pediatr Infect Dis J 30 Suppl 1 2011 25 29
100. E.J. Anderson, A. Rupp, S.T. Shulman, D. Wang, X. Zheng, and G.A. Noskin Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children Pediatrics 127 2011 e264 e270
101. J. Cortes, A.T. Curns, J.E. Tate, M.M. Cortese, M.M.M. Patel, and F. Zhou Rotavirus vaccine and health care utilization for diarrhea in U.S. children N Engl J Med 365 2011 1108 1111
102. F. Martinón-Torres, M.B. Bouzón Alejandro, L.R. Redondo Collazo, J.M. Sánchez Lastres, S.P. Pértega Díaz, and M.T. Seoane Pillado Effectiveness of rotavirus vaccination in Spain Hum Vaccin 7 2011 e1 e4
103. M. Paulke-Korinek, M. Kundi, P. Rendi-Wagner, A. de Martin, G. Eder, and B. Schmidle-Loss Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria Vaccine 29 2011 2791 2796
104. T. Vesikari, P. Van Damme, C. Giaquinto, J. Gray, J. Mrukowicz, and R. Dagan European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe J Pediatr Gastroenterol Nutr 46 Suppl 2 2008 38 48
105. World Health organization (WHO) Safety of rotavirus vaccines: postmarketing surveillance in the WHO Region of the Americas Wkly Epidemiol Rec 86 2011 66 72
106. M.M. Patel, V.R. López-Collada, M.M. Bulhões, L.H. De Oliveira, A. Bautista Márquez, and B. Flannery Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil N Engl J Med 364 2011 2283 2292
107. M.M. Patel, D. Steele, J.R. Gentsch, J. Wecker, R.I. Glass, and U.D. Parashar Real-world impact of rotavirus vaccination Pediatr Infect Dis J 30 Suppl 1 2011 1 5
108. J.G. Victoria, C. Wang, M.S. Jones, C. Jaing, K. McLoughlin, and S. Gardner Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus J Virol 84 2010 6033 6040
109. Rotavirus vaccination-WHO does not recommend any change to use of Rotarix vaccine [último acceso 12 Oct 2011]. Disponible en: http://www.who.int/ immunization/newsroom/news-rotavirus-vaccine-use/en/index.html
110. FDA Revises Recommendations for Rotavirus Vaccines [último acceso 12 Oct 2011]. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2010/ucm212149
111. European Medicines Agency confirms positive benefit-risk balance of Rotarix. Porcine circovirus type 1 in the oral vaccine poses no risk to public health [último acceso 12 Oct 2011]. Disponible en: http://www.ema.europa. eu/ema/index.jsp?curl=pages/news-and-events/news/2010/07/news-detail-001059. jsp&murl=menus/news-and-events/news-and-events.jsp&mid= WC0b01ac058004d5c1&jsenabled=true
112. European Medicines Agency confirms positive benefit-risk balance of RotaTeq [último acceso 12 Oct 2011]. Disponible en: http://www.ema. europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2010/09/ news-detail-001121.jsp&murl=menus/news-and-events/news-and-events. jsp&mid=WC0b01ac058004d5c1&jsenabled=true
113. S.A. Baylis, T. Finsterbusch, N. Bannert, J. Blümel, and A. Mankertz Analysis of porcine circovirus type 1 detected in Rotarix vaccine Vaccine 29 2011 690 697
114. Detección de ADN. de circovirus porcino en las vacunas frente a rotavirus: Rotarix® y RotaTeq®. Documento de consenso de las sociedades científicas AEP, AEV, SEIP y SEGHNP. Actualización del 3 de diciembre de 2010 [último acceso 12 Oct 2011]. Disponible en: http://vacunasaep.org/sites/vacunasaep.org/files/Vac-RV-AEP-AEV-SEIP-SEGHNP-dic- 2010-3.pdf
115. T. Vesikari, D.O. Matson, P. Dennehy, P. Van Damme, M. Santosham, and Z. Rodríguez Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine N Eng J Med 354 2006 23 33 (Pubitemid 43048948)
116. G.M. Ruiz-Palacios, I. Pérez-Shael, R. Velázquez, H. Abate, T. Breuer, and S.A. Costa-Clemens Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis N Eng J Med 354 2006 11 22 (Pubitemid 43048947)
117. J.P. Buttery, M.H. Danchin, K.J. Lee, J.B. Carlin, P.B. McIntyre, and E.J. Elliott Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia Vaccine 29 2011 3061 3066
118. World Health Organization (WHO) Rotavirus vaccine and intussusception: report from an expert consultation Wkly Epidem Rec 86 2011 317 324
119. H.B. Greenberg Rotavirus vaccination and intussusception-act two N Engl J Med 364 2011 2354 2355
120. Nota informativa: Liberación de lotes de la vacuna Rotateq®. AEMPS, 4 noviembre 2010 [último acceso 12 Oct 2011]. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/calidad/ 2010/NI-circovirus-rotateq-noviembre-2010.htm
121. D. Moreno-Pérez, J. Arístegui Fernández, J. Ruiz-Contreras, F.J. Álvarez García, M. Merino Moína, and J. González Hachero Vacunación frente a la gripe estacional en la infancia y la adolescencia. Recomendaciones del CAV-AEP para la campaña 2011-2012 An Pediatr (Barc) 76 2012 66.e1 66.e5
122. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season OMS [último acceso 12 Oct 2011]. Disponible en: http://www.who.int/ influenza/vaccines/virus/recommendations/2011-09-recommendation.pdf
123. P.L. Fraaij, and T. Heikkinen Seasonal influenza: the burden of disease in children Vaccine 29 2011 7524 7528
124. S. Esposito, C. Daleno, F. Baldanti, A. Scala, G. Campanini, and F. Taroni Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus Virol J 8 2011 349
125. H. Silvennoinen, V. Peltola, R. Vainionpaa, O. Ruuskunen, and T. Heikkinen Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study Pediatr Infect Dis J 30 2011 e24 e28
126. K.A. Poehling, K.M. Edwards, G.A. Weinberg, P. Szilagyi, M.A. Staat, and M.K. Iwane The underrecognized burden of influenza in young children N Engl J Med 355 2006 31 40
127. T. Jefferson, A. Rivetti, A. Harnden, C. Di Pietrantonj, and V. Demicheli Vaccines for preventing influenza in healthy children Cochrane Database Syst Rev 2008 CD004879
128. Centers for Disease Control and Prevention (CDC) Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 60 2011 1128 1132 [último acceso 12 Oct 2011]. Disponible en: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm6033a3.htm?s-cid=mm6033a3-w
129. Comité Asesor de Vacunas de la Asociación Española de Pediatría Fichas técnicas de vacunas antigripales [último acceso 12 Oct 2011]. Disponible en: http://vacunasaep.org/profesionales/fichas- tecnicas-vacunas/resultados?diseases=148
130. American Academy of Pediatrics Committee on Infectious Diseases Hepatitis A vaccine recommendations Pediatrics 120 2007 189 199
131. A. Domínguez, L. Salleras, G. Carmona, and J. Batalla Effectiveness of a mass hepatitis A vaccination program in preadolescents Vaccine 21 2003 698 701 (Pubitemid 36091981)
132. A. Domínguez, M. Oviedo, G. Carmona, J.M. Jansá, E. Borrás, and L. Salleras Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia, Spain J Viral Hepat 15 Suppl. 2 2008 51 56
133. A. Domínguez, M. Oviedo, G. Carmona, J. Batalla, M. Bruguera, and L. Salleras Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction Vaccine 26 2008 1737 1741
134. C. Rodríguez, L. Basile, L. Urbiztondo, E. Borràs, and J. Batalla Vacunación antihepatitis A: ¿selectiva o universal? Vacunas 10 2009 4 8
135. A. Deasy, and R.C. Read Challenges for development of meningococcal vaccines in infants and children Expert Rev Vaccines 10 2011 335 343
136. E.L. Su, and M.D. Snape A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease Expert Rev Vaccines 10 2011 575 588
137. W.D. Zollinger, J.T. Poolman, and M.C.J. Maiden Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines 10 2011 559 561
138. Centers for Disease Control and Prevention (CDC). Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind [último acceso 12 Oct 2011]. Disponible en: http://www.cdc.gov/vaccines/recs/schedules/downloads/child/catchup-schedule-pr. pdf
139. The Australian Immunisation Handbook, 9th Edition, 2008. Catch-up - updated July 2009 [último acceso 12 Oct 2011]. Disponible en: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/ handbook-catchup